Help
RSS
API
Feed
Maltego
Contact
Domain > degezonheidszorg.org
×
Welcome!
Right click nodes and scroll the mouse to navigate the graph.
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2018-09-06
85.25.107.247
(
ClassC
)
2024-11-14
172.67.180.253
(
ClassC
)
Port 80
HTTP/1.1 200 OKDate: Thu, 14 Nov 2024 22:23:36 GMTContent-Type: text/html; charsetuft-8Transfer-Encoding: chunkedConnection: keep-aliveX-Powered-By: PHP/5.4.45cf-cache-status: DYNAMICvary: accept-encodingReport-To: {endpoints:{url:https:\/\/a.nel.cloudflare.com\/report\/v4?sJ4%2BLVy8j5Njri07y3jjdaCFQpDoSRPtVIcjTcjHoZMVUBKvSQFyiPiA0rXwMJHDyHvJtjcxK36NFGW%2BCRfs1p7fib1et2SaLog9cE53JYwZA7NjcO4CadLgsvR3C2jjbv%2F4UFFgqSw%3D%3D},group:cf-nel,max_age:604800}NEL: {success_fraction:0,report_to:cf-nel,max_age:604800}Server: cloudflareCF-RAY: 8e2a682aaa50b9c1-SEAalt-svc: h3:443; ma86400server-timing: cfL4;desc?protoTCP&rtt9480&sent1&recv3&lost0&retrans0&sent_bytes0&recv_bytes59&delivery_rate0&cwnd249&unsent_bytes0&cid0000000000000000&ts0&x0 !DOCTYPE html PUBLIC -//W3C//DTD XHTML 1.0 Transitional//EN http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd>html xmlnshttp://www.w3.org/1999/xhtml dirltr langen-US> head profilehttp://gmpg.org/xfn/11> meta http-equivContent-Type contenttext/html; charsetUTF-8 /> title>Womens Healthcare News/title> meta namedescription content /> meta namekeywords content /> link relstylesheet href/css/style.css typetext/css mediascreen /> link relstylesheet href/css/ie.css typetext/css mediascreen /> /head> body classhome blog> div idheader> div classpageList> ul> /ul> /div> /div> div idmainWrap> div idmain> div idsiteDescription> h2> /h2> /div> div idcontent> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/statins-protect-smokers-from-lung-damage relbookmark titleStatins Protect Smokers From Lung Damage>Statins Protect Smokers From Lung Damage/a>/h3> div classpostDate> span classmonth>21/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>Statins, the widely used class of drugs for cholesterol management, are now showing promising results in slowing smoking-induced lung damage. In a new study presented at CHEST 2006, the 72nd annual international scientific assembly of the American College of Chest Physicians (ACCP), current and former smokers who used statins had lower lung function decline than those not using statins, regardless of whether patients continued or stopped smoking.br>br> Until now, no medication has.../p> /div> /div> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/pervasis-therapeutics-receives-fda-clearance-for-pivotal-phase-3-trial-of-vascugel(r) relbookmark titlePervasis Therapeutics Receives FDA Clearance For Pivotal Phase 3 Trial Of Vascugel(R)>Pervasis Therapeutics Receives FDA Clearance For Pivotal Phase 3 Trial Of Vascugel(R)/a>/h3> div classpostDate> span classmonth>20/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>Pervasis Therapeutics, Inc. announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure. The agreement was made under the FDAs Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study in 2010.br>br>We are pleased that the FDA approved the SPA agreement and are confident that we now .../p> /div> /div> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/global-conference-focuses-on-hiv-tb-co-epidemic-challenges;-report-finds-international-spending-on-tb-research-only-slightly-increasing relbookmark titleGlobal Conference Focuses On HIV/TB Co-Epidemic Challenges; Report Finds International Spending On TB Research Only Slightly Increasing>Global Conference Focuses On HIV/TB Co-Epidemic Challenges; Report Finds International Spending On TB Research Only Slightly Increasing/a>/h3> div classpostDate> span classmonth>19/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>Conference delegates at the 38th Union World Conference on Lung Health in Cape Town, South Africa, that began on Thursday are focusing on challenges presented by the HIV/TB co-epidemic, the AP/Google reports. Although about one-third of people living with HIV worldwide have TB, the two diseases often are treated separately, according to the AP/Google Nullis, AP/Google, 11/7).BR>BR>About 3,000 HIV/AIDS researchers, government ministers, health officials, advocates and people living with the di.../p> /div> /div> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/new-stroke-prevention-drug-unlikely-to-be-cost-effective-except-in-patients-at-high-risk-of-bleeding relbookmark titleNew stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding>New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding/a>/h3> div classpostDate> span classmonth>18/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>A new study has shown a stroke-prevention drug designed to be an improvement over prior treatments is less cost-effective for most patients than warfarin, the blood thinner with a 50-year history of helping prevent blood clots and strokes. The study, conducted by researchers at Washington University School of Medicine in St. Louis found, however, that the new drug would be cost-effective for those atrial fibrillation patients whose risk of bleeding is high. br>br>The findings are reported .../p> /div> /div> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/study-sheds-light-on-angiogenesis-inhibitors-points-to-limitations-solutions relbookmark titleStudy Sheds Light On Angiogenesis Inhibitors, Points To Limitations, Solutions>Study Sheds Light On Angiogenesis Inhibitors, Points To Limitations, Solutions/a>/h3> div classpostDate> span classmonth>17/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>A new generation of cancer drugs designed to starve tumors of their blood supply - called angiogenesis inhibitors - succeeds at first, but then promotes more invasive cancer growth - sometimes with a higher incidence of metastases, according to a new study in animals. The research clarifies similar findings in other animal studies and is consistent with some early evidence from a small number of clinical trials with cancer patients.br>br>People have thought that angiogenesis-inhibiting th.../p> /div> /div> /div> div idsidebar> div classsidebarBox idrecentPostsBox stylepadding-top:90px;> div classsidebarTitle> h4>Links/h4> /div> ul> li>a href/index.php>Home/a>/li> li>a href/sitemap.php>Sitemap/a>/li> /ul> /div> div classsidebarBox idrecentPostsBox> div classsidebarTitle> h4>Recent Posts/h4> /div> ul>li>a href/post/statins-protect-smokers-from-lung-damage>Statins Protect Smokers From Lung Damage/a>/li>li>a href/post/pervasis-therapeutics-receives-fda-clearance-for-pivotal-phase-3-trial-of-vascugel(r)>Pervasis Therapeutics Receives FDA Clearance For Pivotal Phase 3 Trial Of Vascugel(R)/a>/li>li>a href/post/global-conference-focuses-on-hiv-tb-co-epidemic-challenges;-report-finds-international-spending-on-tb-research-only-slightly-increasing>Global Conference Focuses On HIV/TB Co-Epidemic Challenges; Report Finds International Spending On TB Research Only Slightly Increasing/a>/li>li>a href/post/new-stroke-prevention-drug-unlikely-to-be-cost-effective-except-in-patients-at-high-risk-of-bleeding>New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding/a>/li>li>a href/post/study-sheds-light-on-angiogenesis-inhibitors-points-to-limitations-solutions>Study Sheds Light On Angiogenesis Inhibitors, Points To Limitations, Solutions/a>/li>li>a href/post/report-on-siu-2007-paris-innovations-in-the-treatment-of-stress-urinary-incontinence>Report On SIU 2007 Paris: Innovations In The Treatment Of Stress Urinary Incontinence/a>/li>li>a href/post/seniors-demand-world-class-care-financial-security-equality-in-work-and-an-end-to-ageism-australia>Seniors Demand World Class Care, Financial Security, Equality In Work And An End To Ageism, Australia/a>/li>li>a href/post/zypadhera(tm)-receives-positive-opinion-from-the-european-committee-for-medicinal-products-for-human-use-(chmp)-for-treatment-of-schizophrenia>Zypadhera(TM) Receives Positive Opinion From The European Committee For Medicinal Products For Human Use (CHMP) For Treatment Of Schizophrenia/a>/li>li>a href/post/study-shows-how-light-receptors-in-eye-play-key-role-in-setting-biological-clock>Study Shows How Light Receptors In Eye Play Key Role In Setting Biological Clock/a>/li>li>a href/post/low-dose-and-high-dose-ketoconazole-demonstrate-similar-outcomes-in-patients-with-androgen-independent-prostate-cancer>Low Dose And High Dose Ketoconazole Demonstrate Similar Outcomes In Patients With Androgen-Independent Prostate Cancer/a>/li>li>a href/post/gilbert-hospital-continues-cutting-edge-treatments>Gilbert Hospital Continues Cutting Edge Treatments/a>/li> /ul> /div> /div>div idnavigation> p idprevPage>/p> p idnextPage>/p>/div> div idtagCloud> div classsubTitle> h4>strong>Tag Cloud/strong>/h4> /div> ul> /ul> /div> /div> /div> div idfooter> div classpageList> ul> /ul> /div> div idcopywright> /div> /div>/body>/html>
Port 443
HTTP/1.1 200 OKDate: Thu, 14 Nov 2024 22:23:36 GMTContent-Type: text/html; charsetuft-8Transfer-Encoding: chunkedConnection: keep-aliveX-Powered-By: PHP/5.4.45cf-cache-status: DYNAMICvary: accept-encodingReport-To: {endpoints:{url:https:\/\/a.nel.cloudflare.com\/report\/v4?sMHh2rjBBOyqFKrzhvGxYUnUFjYak7Axo6NwEG%2BuBrjgMB5TBkC3ZWSaPEVhXeRAn4eDMp1Lru%2BW8OukLBBIB8X%2BiXz9Ql5TpgqMukKhu8GbZTGmtW68UiZeirTFEgYy4u98U90NkQA%3D%3D},group:cf-nel,max_age:604800}NEL: {success_fraction:0,report_to:cf-nel,max_age:604800}Server: cloudflareCF-RAY: 8e2a682c0f7ddf27-SEAalt-svc: h3:443; ma86400server-timing: cfL4;desc?protoTCP&rtt9504&sent5&recv6&lost0&retrans0&sent_bytes2876&recv_bytes731&delivery_rate308117&cwnd253&unsent_bytes0&cid6b0c57b525d829ea&ts190&x0 !DOCTYPE html PUBLIC -//W3C//DTD XHTML 1.0 Transitional//EN http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd>html xmlnshttp://www.w3.org/1999/xhtml dirltr langen-US> head profilehttp://gmpg.org/xfn/11> meta http-equivContent-Type contenttext/html; charsetUTF-8 /> title>Womens Healthcare News/title> meta namedescription content /> meta namekeywords content /> link relstylesheet href/css/style.css typetext/css mediascreen /> link relstylesheet href/css/ie.css typetext/css mediascreen /> /head> body classhome blog> div idheader> div classpageList> ul> /ul> /div> /div> div idmainWrap> div idmain> div idsiteDescription> h2> /h2> /div> div idcontent> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/statins-protect-smokers-from-lung-damage relbookmark titleStatins Protect Smokers From Lung Damage>Statins Protect Smokers From Lung Damage/a>/h3> div classpostDate> span classmonth>21/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>Statins, the widely used class of drugs for cholesterol management, are now showing promising results in slowing smoking-induced lung damage. In a new study presented at CHEST 2006, the 72nd annual international scientific assembly of the American College of Chest Physicians (ACCP), current and former smokers who used statins had lower lung function decline than those not using statins, regardless of whether patients continued or stopped smoking.br>br> Until now, no medication has.../p> /div> /div> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/pervasis-therapeutics-receives-fda-clearance-for-pivotal-phase-3-trial-of-vascugel(r) relbookmark titlePervasis Therapeutics Receives FDA Clearance For Pivotal Phase 3 Trial Of Vascugel(R)>Pervasis Therapeutics Receives FDA Clearance For Pivotal Phase 3 Trial Of Vascugel(R)/a>/h3> div classpostDate> span classmonth>20/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>Pervasis Therapeutics, Inc. announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure. The agreement was made under the FDAs Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study in 2010.br>br>We are pleased that the FDA approved the SPA agreement and are confident that we now .../p> /div> /div> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/global-conference-focuses-on-hiv-tb-co-epidemic-challenges;-report-finds-international-spending-on-tb-research-only-slightly-increasing relbookmark titleGlobal Conference Focuses On HIV/TB Co-Epidemic Challenges; Report Finds International Spending On TB Research Only Slightly Increasing>Global Conference Focuses On HIV/TB Co-Epidemic Challenges; Report Finds International Spending On TB Research Only Slightly Increasing/a>/h3> div classpostDate> span classmonth>19/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>Conference delegates at the 38th Union World Conference on Lung Health in Cape Town, South Africa, that began on Thursday are focusing on challenges presented by the HIV/TB co-epidemic, the AP/Google reports. Although about one-third of people living with HIV worldwide have TB, the two diseases often are treated separately, according to the AP/Google Nullis, AP/Google, 11/7).BR>BR>About 3,000 HIV/AIDS researchers, government ministers, health officials, advocates and people living with the di.../p> /div> /div> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/new-stroke-prevention-drug-unlikely-to-be-cost-effective-except-in-patients-at-high-risk-of-bleeding relbookmark titleNew stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding>New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding/a>/h3> div classpostDate> span classmonth>18/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>A new study has shown a stroke-prevention drug designed to be an improvement over prior treatments is less cost-effective for most patients than warfarin, the blood thinner with a 50-year history of helping prevent blood clots and strokes. The study, conducted by researchers at Washington University School of Medicine in St. Louis found, however, that the new drug would be cost-effective for those atrial fibrillation patients whose risk of bleeding is high. br>br>The findings are reported .../p> /div> /div> div classpost-178 post type-post status-publish format-standard hentry category-uncategorized> div classmainTitle> h3>a href/post/study-sheds-light-on-angiogenesis-inhibitors-points-to-limitations-solutions relbookmark titleStudy Sheds Light On Angiogenesis Inhibitors, Points To Limitations, Solutions>Study Sheds Light On Angiogenesis Inhibitors, Points To Limitations, Solutions/a>/h3> div classpostDate> span classmonth>17/span> span classday>04/span> span classyear>2016/span> /div> /div> div classentry> p>A new generation of cancer drugs designed to starve tumors of their blood supply - called angiogenesis inhibitors - succeeds at first, but then promotes more invasive cancer growth - sometimes with a higher incidence of metastases, according to a new study in animals. The research clarifies similar findings in other animal studies and is consistent with some early evidence from a small number of clinical trials with cancer patients.br>br>People have thought that angiogenesis-inhibiting th.../p> /div> /div> /div> div idsidebar> div classsidebarBox idrecentPostsBox stylepadding-top:90px;> div classsidebarTitle> h4>Links/h4> /div> ul> li>a href/index.php>Home/a>/li> li>a href/sitemap.php>Sitemap/a>/li> /ul> /div> div classsidebarBox idrecentPostsBox> div classsidebarTitle> h4>Recent Posts/h4> /div> ul>li>a href/post/statins-protect-smokers-from-lung-damage>Statins Protect Smokers From Lung Damage/a>/li>li>a href/post/pervasis-therapeutics-receives-fda-clearance-for-pivotal-phase-3-trial-of-vascugel(r)>Pervasis Therapeutics Receives FDA Clearance For Pivotal Phase 3 Trial Of Vascugel(R)/a>/li>li>a href/post/global-conference-focuses-on-hiv-tb-co-epidemic-challenges;-report-finds-international-spending-on-tb-research-only-slightly-increasing>Global Conference Focuses On HIV/TB Co-Epidemic Challenges; Report Finds International Spending On TB Research Only Slightly Increasing/a>/li>li>a href/post/new-stroke-prevention-drug-unlikely-to-be-cost-effective-except-in-patients-at-high-risk-of-bleeding>New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding/a>/li>li>a href/post/study-sheds-light-on-angiogenesis-inhibitors-points-to-limitations-solutions>Study Sheds Light On Angiogenesis Inhibitors, Points To Limitations, Solutions/a>/li>li>a href/post/report-on-siu-2007-paris-innovations-in-the-treatment-of-stress-urinary-incontinence>Report On SIU 2007 Paris: Innovations In The Treatment Of Stress Urinary Incontinence/a>/li>li>a href/post/seniors-demand-world-class-care-financial-security-equality-in-work-and-an-end-to-ageism-australia>Seniors Demand World Class Care, Financial Security, Equality In Work And An End To Ageism, Australia/a>/li>li>a href/post/zypadhera(tm)-receives-positive-opinion-from-the-european-committee-for-medicinal-products-for-human-use-(chmp)-for-treatment-of-schizophrenia>Zypadhera(TM) Receives Positive Opinion From The European Committee For Medicinal Products For Human Use (CHMP) For Treatment Of Schizophrenia/a>/li>li>a href/post/study-shows-how-light-receptors-in-eye-play-key-role-in-setting-biological-clock>Study Shows How Light Receptors In Eye Play Key Role In Setting Biological Clock/a>/li>li>a href/post/low-dose-and-high-dose-ketoconazole-demonstrate-similar-outcomes-in-patients-with-androgen-independent-prostate-cancer>Low Dose And High Dose Ketoconazole Demonstrate Similar Outcomes In Patients With Androgen-Independent Prostate Cancer/a>/li>li>a href/post/gilbert-hospital-continues-cutting-edge-treatments>Gilbert Hospital Continues Cutting Edge Treatments/a>/li> /ul> /div> /div>div idnavigation> p idprevPage>/p> p idnextPage>/p>/div> div idtagCloud> div classsubTitle> h4>strong>Tag Cloud/strong>/h4> /div> ul> /ul> /div> /div> /div> div idfooter> div classpageList> ul> /ul> /div> div idcopywright> /div> /div>/body>/html>
Subdomains
Date
Domain
IP
www.degezonheidszorg.org
2024-11-14
104.21.96.132
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]